% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • whippersnapper65 whippersnapper65 Sep 4, 2013 10:26 PM Flag

    Wedbush comments suggest an EARLY STOP for ACT-IV trial for efficacy!!!

    "Upside from $35/share could come from ACT IV stopping early (potentially worth $14/share from earlier commercialization and reduced risk)"

    The fact that an investment firm is even suggesting the possibility that Rindopepimut's registrational trial could be halted early for statistical significance that proves efficacy is HUGE!

    Do they know something? Those analysts are paid very well to turn over every stone. Hmm......

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
3.26+0.07(+2.15%)Oct 25 4:00 PMEDT